Privia Health在2025年第4季度打破了对收入的预期,但高估值和内幕销售引起了关注。 Privia Health beat earnings expectations in Q4 2025, but high valuation and insider selling raise concerns.

Privia卫生小组报告,2026年2月26日,Q4收入丰厚,25美元的EPS和5.4117亿美元的收入超过预期。 Privia Health Group reported strong Q4 earnings on February 26, 2026, with $0.25 EPS and $541.17 million in revenue, surpassing expectations. 该股票于3月16日以21.96美元关闭,内部销售商包括CFO David Mountcastle和CEO Parth Mehrotra以21.52至25.05美元的价格出售数千股股票。 The stock closed at $21.96 on March 16, with insider sales including CFO David Mountcastle and CEO Parth Mehrotra selling thousands of shares at prices between $21.52 and $25.05. 该公司的P/E比率高达129.18, 引起了估值方面的关切。 Despite the earnings beat and a “Moderate Buy” analyst rating, the company’s high P/E ratio of 129.18 raises valuation concerns.